Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

Authors:

Abstract
(2009). Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion: Vol. 25, No. 2, pp. 401-411. doi: 10.1185/03007990802636817

This publication has 45 references indexed in Scilit: